External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology SGO 2021
Roche and Genentech at

SGO 2021

March 19 - March 25
Virtual
sgo.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
10:30 AM
Duration 7mins Virtual
Association of BRCA, homologous recombination deficiency (HRD), and PD-L1 with clinical outcomes in patients receiving atezolizumab vs placebo combined wtih chemotherapy + bevacizumab for newly diagnosed ovarian cancer: Exploratory analyses from IMagyn050/GOG 3015/ENGOT-OV39
Landen CN, Molinero L, Sehouli J, Miller A, Moore KN, Taskiran C, Bookman M, Lindemann K, Anderson C, Berger R, Myers T, Beiner M, Reid T, Van Nieuwenhuysen E, Green A, Okamoto A, Aghajanian A, Thaker P, Blank S, Khor V, Wu F, Lin YG, Pignata S
Oncology | Ovarian Cancer - Cervical Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.